JP Morgan Chase
KYNB

JP Morgan Chase’s Kyntra Bio KYNB Stock Holding History

JP Morgan Chase’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$88 Hold
12
– – ﹤0.01% 7546
2026
Q1 		$78 Hold
12
– – ﹤0.01% 7327
2025
Q4 		$105 Hold
12
– – ﹤0.01% 7207
2025
Q3 		$147 Hold
12
– – ﹤0.01% 7144
2025
Q2 		$64 Sell
12
-37
-76% -$270 ﹤0.01% 6879
2025
Q1 		$379 Buy
49
+26
+113% +$312 ﹤0.01% 6727
2024
Q4 		$300 Sell
23
-66,919
-100% -$622K ﹤0.01% 6863
2024
Q3 		$668K Buy
66,942
+54,328
+431% +$820K ﹤0.01% 4720
2024
Q2 		$281K Buy
12,614
+8,670
+220% +$268K ﹤0.01% 4970
2024
Q1 		$232K Buy
3,944
+1,539
+64% +$66.3K ﹤0.01% 5270
2023
Q4 		$53.3K Sell
2,405
-2,786
-54% -$42K ﹤0.01% 5980
2023
Q3 		$112K Sell
5,191
-79
-1% -$3.1K ﹤0.01% 5405
2023
Q2 		$356K Sell
5,270
-1,462
-22% -$605K ﹤0.01% 4705
2023
Q1 		$3.14M Sell
6,732
-470
-7% -$249K ﹤0.01% 3181
2022
Q4 		$2.88M Buy
7,202
+1,527
+27% +$585K ﹤0.01% 3277
2022
Q3 		$1.85M Sell
5,675
-30
-0.5% -$9.66K ﹤0.01% 3541
2022
Q2 		$1.51M Buy
5,705
+819
+17% +$209K ﹤0.01% 3771
2022
Q1 		$1.47M Sell
4,886
-78
-2% -$27.2K ﹤0.01% 3999
2021
Q4 		$1.75M Sell
4,964
-46,035
-90% -$14.3M ﹤0.01% 3950
2021
Q3 		$13M Sell
50,999
-38,930
-43% -$13.8M ﹤0.01% 2150
2021
Q2 		$59.9M Buy
89,929
+2,752
+3% +$1.59M 0.01% 1129
2021
Q1 		$75.6M Buy
87,177
+4,434
+5% +$4.72M 0.01% 980
2020
Q4 		$76.7M Buy
82,743
+5,542
+7% +$5.83M 0.01% 885
2020
Q3 		$80.3M Buy
77,201
+6,121
+9% +$6.59M 0.01% 775
2020
Q2 		$72M Buy
71,080
+3,826
+6% +$3.55M 0.01% 759
2020
Q1 		$58.4M Sell
67,254
-5,800
-8% -$5.77M 0.01% 748
2019
Q4 		$78.3M Buy
73,054
+1,254
+2% +$1.28M 0.01% 760
2019
Q3 		$66.4M Buy
71,800
+4,357
+6% +$4.79M 0.01% 814
2019
Q2 		$75.1M Buy
67,443
+18,141
+37% +$19.9M 0.01% 785
2019
Q1 		$67M Buy
49,302
+1,382
+3% +$1.87M 0.01% 823
2018
Q4 		$55.4M Buy
47,920
+1,581
+3% +$1.78M 0.01% 856
2018
Q3 		$70.4M Buy
46,339
+3,883
+9% +$5.98M 0.01% 854
2018
Q2 		$66.4M Buy
42,456
+3,881
+10% +$5.06M 0.01% 837
2018
Q1 		$44.6M Sell
38,575
-3,237
-8% -$4.26M 0.01% 1004
2017
Q4 		$49.5M Buy
41,812
+1,318
+3% +$1.65M 0.01% 990
2017
Q3 		$54.1M Sell
40,494
-2,337
-5% -$2.46M 0.01% 886
2017
Q2 		$34.6M Sell
42,831
-2,631
-6% -$1.83M 0.01% 1109
2017
Q1 		$28M Buy
45,462
+2,973
+7% +$1.81M 0.01% 1249
2016
Q4 		$22.7M Sell
42,489
-591
-1% -$295K 0.01% 1385
2016
Q3 		$22.3M Sell
43,080
-8,232
-16% -$3.88M 0.01% 1304
2016
Q2 		$21.1M Buy
51,312
+139
+0.3% +$63.6K 0.01% 1364
2016
Q1 		$27.2M Sell
51,173
-18,980
-27% -$9.46M 0.01% 1134
2015
Q4 		$53.4M Buy
70,153
+5,899
+9% +$3.91M 0.01% 781
2015
Q3 		$35.2M Buy
64,254
+121
+0.2% +$73.3K 0.01% 950
2015
Q2 		$37.7M Buy
64,133
+44,903
+234% +$26.1M 0.01% 1026
2015
Q1 		$15.1M Sell
19,230
-11,276
-37% -$8.74M ﹤0.01% 1629
2014
Q4 		$20.9M Buy
+30,506
New +$19.6M ﹤0.01% 1446

Other funds holding KYNB

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

JP Morgan Chase's KYNB Position: Q2 2026 in Review

JP Morgan Chase held its Kyntra Bio (KYNB) position steady in Q2 2026 at 12 shares worth $88. The position accounts for ﹤0.01% of the portfolio, ranked #7546.

JP Morgan Chase first reported a position in KYNB in Q4 2014 and has held it in 47 quarters since. The position peaked at $80.3M in Q3 2020. 27 funds tracked by Wall St. Rank hold KYNB as of Q2 2026.

  • JP Morgan Chase held 12 shares of Kyntra Bio worth $88 as of Q2 2026.
  • JP Morgan Chase left its Kyntra Bio share count unchanged in Q2 2026.
  • Kyntra Bio made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #7546 holding.
  • JP Morgan Chase first reported a position in Kyntra Bio in Q4 2014 and has held it in 47 quarters since.
  • JP Morgan Chase's Kyntra Bio position peaked at $80.3M in Q3 2020.
  • 27 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.